Mankind Pharma Q1 FY27 PAT up 35% YoY, Rs 150 cr guarantee to BSV

Emphasis Of MatterPat Growth 25pctResults RestatedExceptional ItemEbitda Margin ExpansionRelated Party TransactionsResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.8%Reaction day

₹2569.90

prior close

₹2604.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.5%-4.3% vs market

Pharmaceuticals peers, median of 164sector+0.1%-3.9% vs sector

On the reaction day the stock moved 4.3 pts less than Nifty Midcap 150 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.2

10m

-5.8

15m

-5.1

30m

-5.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.8+0.5-4.3+0.1-3.9

Next day

-3.4+1.7-5.1+1.1-4.5

-4.5+1.4-5.8+1.0-5.5

-5.1+1.6-6.7+1.1-6.2

-5.8+1.2-7.0+1.2-7.0

-4.5+1.4-5.9+1.5-6.0

-5.5+1.9-7.4+2.3-7.8

15d

-7.2+1.6-8.9+1.3-8.6

-5.9+2.2-8.1+2.3-8.2

-2.6-5.1+2.5+3.2-5.7

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma Q1 FY27 standalone revenue up 15% to Rs 2,964 cr, PAT jumped 35% YoY to Rs 558 cr. Consolidated revenue grew 13% to Rs 4,031 cr, PAT up 29% to Rs 574 cr. Board approved Rs 150 cr corporate guarantee for BSV subsidiary. Q1 FY26 figures restated for BSV business combination. Auditors flagged Rs 1,869 cr income tax proceedings as Emphasis of Matter; company expects no material impact.

Likely market impact

Strong quarterly earnings with 35% standalone PAT growth and 13% revenue rise. Subsidiary guarantee and ongoing tax dispute remain risks to watch.